Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine

International Clinical Psychopharmacology

Volumn 29, Issue 5, 2014, Pages 239-251

  Lam, Raymond W ^a   Endicott, Jean ^c   Hsu, Ming Ann ^b   Fayyad, Rana ^b   Guico Pabia, Christine ^d   Boucher, Matthieu ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PFIZER INC   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d CGP Strategic Solutions LLC   (United States)

Author keywords

antidepressive agents; functional outcomes; major depressive disorder

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; NEUROTRANSMITTER UPTAKE INHIBITOR; O-DESMETHYLVENLAFAXINE;

ADULT; AGED; CANADA; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EMPLOYMENT; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PRODUCTIVITY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SEVERITY OF ILLNESS INDEX; TIME; UNITED STATES; YOUNG ADULT;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; CANADA; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; EFFICIENCY; EMPLOYMENT; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; PSYCHIATRIC STATUS RATING SCALES; SELF REPORT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84906079566     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000031     Document Type: Article

References (39)

1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, Text Revision: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Publishing
2. Bech P (2005). Social functioning: Should it become an endpoint in trials of antidepressants? CNS Drugs 19: 313-324
3. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, et al. (2005). Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 62: 409-416
4. Druss BG, Rosenheck RA, Sledge WH (2000). Health and disability costs of depressive illness in a major U.S. corporation. Am J Psychiatry 157: 1274-1278
5. Dunlop BW, Aaron MH (2010). Response to treatment with placebo, medication or psychotherapy in severe non-psychotic major depressive disorder. Curr Psychiatry Rev 6: 28-45
6. Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ (2011). Symptomatic and functional improvement in employed depressed patients: A double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol 31: 569-576
7. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME (2000). Fluoxetine versus sertraline and paroxetine in major depression: Tolerability and efficacy in anxious depression. J Affect Disord 59: 119-126
8. Greer TL, Kurian BT, Trivedi MH (2010). Defining and measuring functional recovery from depression. CNS Drugs 24: 267-284
9. Guico-Pabia CJ, Fayyad RS, Soares CN (2012). Assessing the relationship between functional impairment/recovery and depression severity: A pooled analysis. Int Clin Psychopharmacol 27: 1-7
10. Guy W (1976). Clinical Global Impressions. ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare. pp. 217-222
11. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62
12. Hirschfeld RM, Montgomery SA, Keller MB, Kasper S, Schatzberg AF, Möller HJ, et al. (2000). Social functioning in depression: A review. J Clin Psychiatry 61: 268-275
13. Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, et al. (2002). Partial response and nonresponse to antidepressant therapy: Current approaches and treatment options. J Clin Psychiatry 63: 826-837
14. Judge R, Plewes JM, Kumar V, Koke SC, Kopp JB (2000). Changes in energy during treatment of depression: An analysis of fluoxetine in double-blind, placebo-controlled trials. J Clin Psychopharmacol 20: 666-672
15. Kocsis JH, Schatzberg A, Rush AJ, Klein DN, Howland R, Gniewesch L, et al. (2002). Psychosocial outcomes following long-Term, double-blind treatment of chronic depression with sertraline vs placebo. Arch Gen Psychiatry 59: 723-728
16. Kok RM, van Baarsen C, Nolen WA, Heeren TJ (2009). Early response as predictor of final remission in elderly depressed patients. Int J Geriatr Psychiatry 24: 1299-1303
17. Lam RW, Filteau MJ, Milev R (2011). Clinical effectiveness: The importance of psychosocial functioning outcomes. J Affect Disord 132 (Suppl 1): S9-S13
18. Lam RW (2012). Onset, time course and trajectories of improvement with antidepressants. Eur Neuropsychopharmacol 12: S492-S498
19. Lam RW, Michalak EE, Bond DJ, Tam EM, Axler A, Yatham LN (2012). Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning? Depress Res Treat 2012: 630206
20. Langlieb AM, Guico-Pabia CJ (2010). Beyond symptomatic improvement: Assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion J Clin Psychiatry 12: E1-e14
21. Mathers CD, Loncar D (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: E442
22. McKnight PE, Kashdan TB (2009). The importance of functional impairment to mental health outcomes: A case for reassessing our goals in depression treatment research. Clin Psychol Rev 29: 243-259
23. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389
24. Oakes TM, Myers AL, Marangell LB, Ahl J, Prakash A, Thase ME, Kornstein SG (2012). Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: Primary outcomes from two trials conducted under the same protocol. Hum Psychopharmacol 27: 47-56
25. Papakostas GI (2009). Major depressive disorder: Psychosocial impairment and key considerations in functional improvement. Am J Manag Care 15 (Suppl): S316-S321
26. Pfizer Canada Inc. (2013). Pristiq [product monograph] Kirkland, QC, Canada: Pfizer Canada Inc
27. Reilly MC, Zbrozek AS, Dukes EM (1993). The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4: 353-365
28. Sheehan DV (2000). Sheehan disability scale. In: Rush AJ, Pincus HA, First MB, editors. Handbook of psychiatric measures. Washington, DC: American Psychiatric Association. pp. 113-115
29. Sheehan KH, Sheehan DV (2008). Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 23: 70-83
30. Soares CN, Kornstein SG, Thase ME, Jiang Q, Guico-Pabia CJ (2009). Assessing the efficacy of desvenlafaxine for improving functioning and wellbeing outcome measures in patients with major depressive disorder: A pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J Clin Psychiatry 70: 1365-1371
31. Soares CN, Fayyad RS, Guico-Pabia CJ (2014). Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder. J Clin Psychopharmacol 34: 57-65
32. Swindle R, Kroenke K, Braun L (2001). Energy and improved workplace productivity in depression. In: Farquhar I, Summers K, Sorkin A, editors. Investing in health: The social and economic beneftis of health care innovation (research in human capital and development, volume 14). Bingley, UK: Emerald Group Publishing Limited. pp. 323-341
33. Szegedi A, Muller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O (2003). Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 64: 413-420
34. Szegedi A, Jansen WT, van Willigenburg AP, Van Der Meulen E, Stassen HH, Thase ME (2009). Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A metaanalysis including 6562 patients. J Clin Psychiatry 70: 344-353
35. Tollefson GD, Holman SL (1993). Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. Int Clin Psychopharmacol 8: 253-259
36. Trivedi MH, Dunner DL, Kornstein SG, Thase ME, Zajecka JM, Rothschild AJ, et al. (2010). Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord 126: 420-429
37. World Health Organization. 2012 Wellbeing measures in primary health care/ the depcare project. World Health Organization Regional Office for Europe. Available at http: //www.euro.who.int/data/assets/pdf-file/0016/130750/ E60246.pdf. [Accessed 20 March 2012]
38. Wyeth Pharmaceuticals Inc. (2013). Pristiq [package insert]Philadelphia, PA: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc
39. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N, Boerescu D (2006). How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry 163: 148-150.